Dostarlimab

Programmed Death Receptor-1 Blocking Antibody — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Dostarlimab is a drug in the Programmed Death Receptor-1 Blocking Antibody class catalogued in DrugCentral. It was first approved by the EMA in 2021. Its mechanism of action is classified as Programmed Death Receptor-1-directed Antibody Interactions. DrugCentral lists 1 molecular target, including PDCD1. Recorded indications include Recurrent or advanced endometrial cancer.

• Drug class: Programmed Death Receptor-1 Blocking Antibody.
• Mechanism of action: Programmed Death Receptor-1-directed Antibody Interactions.
• Molecular targets: PDCD1 (1 listed in DrugCentral).
• Indications: Recurrent or advanced endometrial cancer.
• ATC code: L01FF07 (PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Recurrent or advanced endometrial cancer

Mechanism & targets

• Mechanism of action (MoA): Programmed Death Receptor-1-directed Antibody Interactions
• Established pharmacologic class: Programmed Death Receptor-1 Blocking Antibody

Molecular targets (1)

Target	Gene	Action	Activity
Programmed cell death protein 1	PDCD1	other	Kd 8.82

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-04-22	FDA	—	GLAXOSMITHKLINE
2021-04-21	EMA	—	GlaxoSmithKline (Ireland) Limited

ATC classification

ATC code	Therapeutic hierarchy
L01FF07	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label · Testing Required
• FDA label · Testing Required
• HCSC label · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Malignant neoplasm progression	487.6
Hypothyroidism	95.1
Adrenal insufficiency	87.6
Toxic skin eruption	85.3
Rash maculo-papular	78.7
Thrombocytopenia	75.4
Acute polyneuropathy	71.5
Myocarditis	66.9
Anaemia	62.8
Colitis	60.9
Immune-mediated lung disease	59.1
Neuropathy peripheral	49.8

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 2022215-59-2
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dostarlimab used for?

DrugCentral lists the following indications for Dostarlimab: Recurrent or advanced endometrial cancer.

How does Dostarlimab work?

Dostarlimab is classified as Programmed Death Receptor-1-directed Antibody Interactions; its molecular targets in DrugCentral include PDCD1.

When was Dostarlimab first approved?

Dostarlimab was first approved by the EMA in 2021.

What drug class does Dostarlimab belong to?

Dostarlimab is in the Programmed Death Receptor-1 Blocking Antibody class.

Sources

• DrugCentral drug card 5451 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4298124 — compound record and bioactivity
• DrugBank DB15627 — drug record
• FDA UNII P0GVQ9A4S5 — substance identity
• DailyMed: FDA labels for Dostarlimab — current prescribing information (label search)
• UniProt Q15116 (PDCD1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.